
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is facing challenges related to competition in the market of generic/biosimilar drugs, which could significantly impact their earnings in the near future. However, their focus on innovation and development of new products, particularly in their immuno-oncology platform with Keytruda, is expected to drive growth in the long term. With strong financials and a diverse portfolio including vaccines and animal health products, Merck is well positioned for continued success in the pharmaceutical industry.
Bears say
Merck & Co is expected to have a weak quarter and year as they face numerous challenges with their Keytruda drug and other pipeline assets, including uncertainty surrounding upcoming data releases. With a recent acquisition and a weak outlook, its valuation has seen little movement and the company has acknowledged risks ranging from climate change to regulatory pressures. Despite low expectations, there is the potential for beats on top and bottom-line results given management's track record and conservative guidance approach.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares